Sanofi-Aventis Voluntarily Pauses Ketek Pediatric Trials Pending FDA Consultation
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision to stop pediatric studies of the antibiotic was not at FDA’s request or due to safety concerns, the company says.